solid tumorsTriTCE Co-StimB cell malignanciesCellTox TM GreenMSD
…timulation, engineered to improve responses in the treatment of solid tumors. Cancer Res. 2024;84(6_Supplement):6719.…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 339 of 245997.9%
oligodendrogliomaSABRACNational Cancer Instituteacid ceramidase inhibitors
…an irreversible inhibitor of AC, was evaluated in an orthotopic oligodendroglioma xenograft mice model using TS603 patient-derived oligodendrogli…
aPD-1head and neck squamous cell carcinomaHNSCCaPD1
…ly upregulated in the aPD-1 + microbubble condition compared to aPD-1 treatment alone (figure 1).Conclusions Our preclinical results …
cutaneous melanomabladder cancerlung cancersimmunotherapyICIsImmunotherapy-relatedimmune checkpoint inhibitors
…red in 36.75% of patients, with certain cancer types, including cutaneous melanoma, bladder cancer, and lung cancers, showing the highest mutation…
solid tumorsDIPGpediatric brain tumorshematologic malignanciespediatric high-grade gliomasdiffuse intrinsic pontine glioma (DIPG)NLVIL13Rα2-targeting 41BB-based CARCAR T cell therapyNLVPMVATV+2 more
… landscape for hematologic malignancies, but its application in solid tumors—especially pediatric brain tumors—remains limited by multiple b…
gastrointestinal cancersimmunotherapyThe Cancer Genome AtlasCheckMate-142KEYNOTE-177CheckMate-142KEYNOTE-059TCGAgastric cancers
…se of programmed death-ligand 1 (PD-L1) immunohistochemistry in gastrointestinal cancers, most immune checkpoint inhibitor trials fail to stratify meani…
nivolumabmetastatic melanomapepinemabipilimumabPepinemab-containingavelumabEmory University
…s, followed by curative-intent surgery and one year of adjuvant nivolumab. Primary study endpoints included multiomic profiling of surgic…
axi-celAxicabtagene Ciloleucelrelapse/refractory LBCLCAR T-cell therapy
…n expanded multi-trial meta-cohort of 586 patients treated with axi-cel. Product characterization was performed with scRNAseq and scATA…
Ewing Sarcomasolid tumorsAZD0754rhabdomyosarcomaosteosarcomaglioblastomahematologic malignanciesTC71Prostate Canceradult cancers
…ng osteosarcoma (143B, SAOS2), rhabdomyosarcoma (RD, Rh30), and Ewing Sarcoma (TC71), were evaluated by ELISA for TGFB cytokine secretion. We…
solid tumorsmelanomaCAR-T cell therapyrelapsed/refractory hematologic malignanciesId3-CARId3CAR-T therapycheckpoint blockade immunotherapy
…e remain key challenges that limit the therapeutic potential in solid tumors. T cells are hardwired to pursue a natural path of differentiat…
TK-6302PRAMEsolid tumorsPRAME-expressing
…g the plethora of challenges raised by solid tumors.Conclusions TK-6302 demonstrates a favorable preclinical safety profile and robust …